Last reviewed · How we verify
Lodotra® — Competitive Intelligence Brief
marketed
Corticosteroid (modified-release formulation)
Glucocorticoid receptor
Immunology / Rheumatology
Small molecule
Live · refreshed every 30 min
Target snapshot
Lodotra® (Lodotra®) — Mundipharma Korea Ltd. Lodotra is a modified-release formulation of prednisone designed to release the corticosteroid in the early morning hours to align with the body's natural cortisol rhythm and reduce morning stiffness in rheumatoid arthritis.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Lodotra® TARGET | Lodotra® | Mundipharma Korea Ltd | marketed | Corticosteroid (modified-release formulation) | Glucocorticoid receptor | |
| Durezol | DIFLUPREDNATE | Novartis | marketed | difluprednate | Glucocorticoid receptor | 2008-01-01 |
| Arnuity Ellipta | FLUTICASONE FUROATE | Haleon Us Holdings | marketed | Corticosteroid | Glucocorticoid receptor | 2007-01-01 |
| Omnaris | CICLESONIDE | Covis | marketed | ciclesonide | Glucocorticoid receptor | 2006-01-01 |
| Omnaris | Alvesco | Takeda Gmbh | marketed | ciclesonide | Glucocorticoid receptor | 2006-01-01 |
| Mifeprex | MIFEPRISTONE | Corcept Therap | marketed | Progestin Antagonist [EPC] | Glucocorticoid receptor | 2000-01-01 |
| Lotemax | LOTEPREDNOL ETABONATE | Bausch Health | marketed | Corticosteroid | Glucocorticoid receptor | 1998-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Omnaris · 8371292 · US
- — Lotemax · 9056057 · Formulation · US
- — Lotemax · 9532955 · Method of Use · US
- — Lotemax · 10058511 · Formulation · US
- — Lotemax · 11219596 · Method of Use · US
- — Lotemax · 11219597 · Method of Use · US
- — Lotemax · 11596599 · Method of Use · US
- — Lotemax · 10857096 · Method of Use · US
- — Lotemax · 10864219 · Method of Use · US
- — Lotemax · 10945948 · Method of Use · US
- — Lotemax · 10940108 · Method of Use · US
- — Lotemax · 9737491 · Method of Use · US
- — Lotemax · 9827191 · Formulation · US
- — Lotemax · 11872318 · Formulation · US
- — Lotemax · 9393213 · Formulation · US
- — Lotemax · 10646436 · Formulation · US
- — Lotemax · 10993908 · Method of Use · US
- — Lotemax · 12115246 · Formulation · US
- — Lotemax · 10688045 · Formulation · US
- — Lotemax · 11642317 · Formulation · US
- — Lotemax · 10646437 · Formulation · US
- — Lotemax · 11534395 · Formulation · US
- — Lotemax · 10596107 · Formulation · US
Sponsor landscape (Corticosteroid (modified-release formulation) class)
- Mundipharma Korea Ltd · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Lodotra® CI watch — RSS
- Lodotra® CI watch — Atom
- Lodotra® CI watch — JSON
- Lodotra® alone — RSS
- Whole Corticosteroid (modified-release formulation) class — RSS
Cite this brief
Drug Landscape (2026). Lodotra® — Competitive Intelligence Brief. https://druglandscape.com/ci/lodotra. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab